Akeso, Inc. (9926.HK) announced that the National Medical Products Administration has approved a significant label update in China for its internally developed, first-in-class PD-1/VEGF bispecific ...

Intensity-modulated proton therapy (IMPT) improves overall survival (OS) and reduces high-grade toxicity compared with intensity-modulated radiation ...

The results of the 3-year follow-up show meaningful improvement in overall survival (OS) and progression-free survival (PFS) for tislelizumab plus chemotherapy compared with placebo plus chemotherapy.

A low prognostic nutritional index may indicate a reduced response to ICIs due to diminished hepatic function and systemic inflammation.

Enzastaurin (ENZ) before and concomitant with radiation therapy (RTX) followed by ENZ maintenance therapy in patients with newly diagnosed glioblastoma (GBM) without hypermethylation of the ...

The second-line administration of ramucirumab in combination with docetaxel has shown a statistically significant improvement in overall survival (OS) and progression-free survival (PFS), compared ...

Lorazepam use may impact progression-free survival and overall survival in patients with a range of cancers, new research suggests. Lorazepam use may impact survival outcomes in patients with a range ...

Forget about Herceptin. There’s a new HER2 agent that ought to be used in HER2-positive stomach cancer, and that’s Jazz ...

Please provide your email address to receive an email when new articles are posted on . Nivolumab significantly prolonged PFS and OS compared with placebo for patients with relapsed malignant ...

Overall survival (OS) is often used as an end point in trials evaluating the efficacy of treatments in colorectal cancer, but measuring this outcome requires prolonged follow-up and the effects of ...

Please provide your email address to receive an email when new articles are posted on . Results of the phase 3 CHOICE-01 trial, presented during a ASCO Plenary Series session, specifically showed PFS ...

Background: An improvement in overall survival (OS) in a randomized controlled study is the gold standard endpoint for the regular approval of new treatments in MBC. Progression-free survival (PFS) ...